The Division of Complex Family Planning at Robert Wood Johnson Medical School provides comprehensive, compassionate, up-to-date reproductive health care for your simple or complex family planning needs.
Our subspecialist-trained family planning gynecologists offer a wide range of services in a comfortable, private, and sensitive environment with a dedicated support staff. We offer care and support for women coping with pregnancy loss, abnormal pregnancies, and unplanned pregnancies. All our patients receive individual attention from our expert physician team who will see you through the counseling, treatment, and follow-up processes.
Our team has years of experience and focused expertise in the management of women with underlying medical conditions and patients who have experienced contraceptive side effects. We will work closely with you to select the most appropriate family planning option and assist you in accessing necessary services. Our services are completely confidential, and your privacy, safety, and comfort are crucial.
Glenmarie Matthews, MD, MBA, MS
Assistant Professor, Family Planning Specialist
Director, Ryan Residency Training Program
Division Chief, Complex Family Planning
Family Planning Services
We provide all birth control options, including IUDs (intrauterine devices), oral contraceptives (the pill), and hormonal implants, as well as permanent sterilization choices. Our contraceptive services include care for women of advanced reproductive age in their forties and those who have co-existing medical conditions and who may need to delay pregnancy.
For patients who qualify, financial assistance is available through the Ryan Residency Training Program to cover a long-acting reversible contraception (LARC) method, such as the hormonal intrauterine device Mirena®, the nonhormonal intrauterine device ParaGard®, and the subdermal contraceptive implant Nexplanon®.
We provide supportive and comprehensive care for miscarriages, abnormal pregnancies, and unplanned pregnancies.
Medical abortion and management of miscarriage through 10 weeks of gestation
In-office surgical abortion and management of miscarriage through 10 weeks of gestation
Surgical abortion and management of fetal death in the second trimester, through 24 weeks of gestation
For those requiring operating room services, hospital staff, and anesthesiology partner with us to provide quality care for high-risk and medically complicated patients.
We accept most commercial insurances and our office staff is available to help you understand your financial responsibilities and assist you in securing insurance coverage.
Commitment to Education and Research
Division of Complex Family Planning offers comprehensive clinical services in a caring, supportive environment designed to meet the needs of our diverse population, while also training young physicians. Our division is home to a Kenneth J. Ryan Residency Training Program in Family Planning, which provides the foundation for resident and medical student family planning education in our department. Family planning research focuses locally and internationally on social, educational, and clinical interventions.
For appointments: (732) 235-6600 or (732) 235-6975
Message from the Chief
Welcome to the Division of Epidemiology and Biostatistics. Established in 1996, this division is perhaps the only one of its kind within an OBGYN department. It offers tremendous research and teaching opportunities in perinatal, reproductive epidemiology, and biostatistics. The Division has a long history of conducting research in reproductive and perinatal epidemiology, as well as women’s health along the life course.
Cande Ananth, PhD, MPH
Professor and Vice Chair for Academic Affairs
Chief, Epidemiology and Biostatistics
Faculty
Cande Ananth, PhD, MPH
Professor
Vice Chair for Academic Affairs
Chief, Epidemiology and Biostatistics
Selected Publications
Accordion Content
Brandt JS, Ananth CV. Placental abruption at near-term and term gestations: pathophysiology, epidemiology, diagnosis, and management. American Journal of Obstetrics and Gynecology 2023 May;228(5S):S1313-S1329. PMID: 37164498; PMCID: PMC10176440.
Fields JC, Graham HL, Brandt JS, Bodenlos K, Ananth CV. Risk of postpartum readmission for depression in relation to ischaemic placental disease: a population-based study. EClinicalMedicine (Lancet). 2023 May 25;60:102011. PMID: 37251629; PMCID: PMC10220321.
Ananth CV, Brandt JS, Keyes KM, Graham HL, Kostis JB, Kostis WJ. Epidemiology and trends in stroke mortality in the USA, 1975-2019. International Journal of Epidemiology 2023 Jun 6;52(3):858-866. PMID: 36343092; PMCID: PMC10244057.
Sachdev D, Yamada R, Lee R, Sauer MV, Ananth CV. Risk of Stroke Hospitalization After Infertility Treatment. JAMA Network Open 2023 Aug 1;6(8):e2331470. PMID: 37647063; PMCID: PMC10469284.
Ananth CV, Rutherford C, Rosenfeld EB, Brandt JS, Graham H, Kostis WJ, Keyes KM. Epidemiologic trends and risk factors associated with the decline in mortality from coronary heart disease in the United States, 1990-2019. American Heart Journal 2023 Sep;263:46-55. PMID: 37178994.
Suarez EA, Huybrechts KF, Straub L, Hernández-Díaz S, Creanga AA, Connery HS, Gray KJ, Vine SM, Jones HE, Bateman BT. Postpartum Opioid-Related Mortality in Patients With Public Insurance. Obstetrics & Gynecology. 2023 Apr 1;141(4):657-665.
Suarez EA, Nguyen M, Zhang D, Zhao Y, Stojanovic D, Munoz M, Liedtka J, Anderson A, Liu W, Dashevsky I, DeLuccia S, Menzin T, Noble J, Maro JC. Monitoring Drug Safety in Pregnancy with Scan Statistics: A Comparison of Two Study Designs. Epidemiology. 2023 Jan 1;34(1):90-98.
Suarez EA, Huybrechts KF, Straub L, Hernández-Díaz S, Jones HE, Connery HS, Davis JM, Gray KJ, Lester B, Terplan M, Mogun H, Bateman BT. Buprenorphine versus Methadone for Opioid Use Disorder in Pregnancy. N Engl J Med. 2022 Dec 1;387(22):2033-2044.
Suarez EA, Bateman BT, Hernández-Díaz S, Straub L, Wisner KL, Gray KJ, Pennell PB, Lester B, McDougle CJ, Zhu Y, Mogun H, Huybrechts KF. Association of Antidepressant Use During Pregnancy With Risk of Neurodevelopmental Disorders in Children. JAMA Internal Medicine. 2022 Oct 3;182(11):1149-60.
Welcome to the Division of General Obstetrics and Gynecology. Our physicians are dedicated to providing state-of-the-art preventive OB/GYN care for the optimal well-being of our patients. Our team approach involves not only our doctors and nurses, but also our patients.
Our group has special interests in:
Female Pelvic Medicine and Reconstructive Surgery
Adolescent health
Perimenopause
Menopause
Chronic vaginal infections
Anthony Monteiro, DO
Assistant Professor
Director, Eric B. Chandler Health Center
Faculty
Charletta Ayers, MD, MPH
Associate Professor
Vice Chair, Clinical Affairs
Gloria Bachmann, MD, MMS
Professor
Vice Chair, Community Affairs
Associate Dean for Women's Health
Director, Women's Health Institute
Lily Bayat, MD, MPH
Assistant Professor
Section of Complex Family Planning
Gary Ebert, MD
Associate Professor
Director, Obstetrics and Gynecology Residency Program
Glenmarie Matthews, MD, MBA, MS
Assistant Professor
Chief, Complex Family Planning
Lena Merjanian, MD
Assistant Professor
Director, Medical Student Clerkship
Director, Pediatric and Adolescent Gynecology
Anthony Monteiro, DO
Assistant Professor
Director, Eric B. Chandler Health Center
Chief of Obstetrics
Fred Nichols, DO
Assistant Professor
Jessica Opoku-Anane, MD, MS
Associate Professor
Section Chief of Benign Gynecologic Surgery
Archana Pradhan, MD, MPH
Professor
Associate Dean for Clinical Education
Director, Undergraduate Medical Education
Fred Silverberg, MD
Assistant Professor
Ezinnem C.N. Ugoji, MD Instructor
Clinical Care Services
State-of-the-art contraception options including ESSURE, a new hysteroscopic contraceptive device
Obstetrical care of low and certain high-risk pregnancies,
Routine gynecologic care
Minimally invasive gynecologic surgery program including colposcopy, hysteroscopy, and laparoscopy
Urogynecologic service
Colposcopy for evaluation of cervical and vaginal dysplasia
Preventive gynecologic care
Prepregnancy counseling
Obstetrical care for low and certain high-risk pregnancies
The Division of Gynecologic Oncology provides continuity of care using different combinations of therapy, including surgery, chemotherapy, biological modifiers, radiation therapy, and the most promising experimental strategies available to women with gynecologic cancer. The team is attentive to a woman’s emotional, social, and family needs in addition to the woman’s health concerns.
James Aikins, MD
Associate Professor
Chief, Gynecologic Oncology
Director, Gynecologic Oncology Fellowship Program
Cancer Institute of New Jersey
Fellowship
Gynecologic Oncology Fellowship Program
The Gynecologic Oncology Fellowship Program is a 3-year program, with 1 year of dedicated research and 2 clinical years focusing on inpatient and outpatient management of patients with gynecologic malignancies.
The Division of Urogynecology and Reconstructive Pelvic Surgery provides state-of-the-art diagnostic and therapeutic options for the full spectrum of urogynecological conditions including urinary incontinence, pelvic organ prolapse, painful bladder syndromes, and birth defects of the genital tract.
One of the most common types of urinary incontinence is stress incontinence, which can be due to a weakness of the pelvic floor muscles or a problem with the urethral sphincter, the muscle that helps hold or release urine. A simple way to describe stress incontinence is a urine leak during physical activity or when you sneeze or laugh.
Women experience urinary incontinence five times as often as men. This is due to the physical stresses of pregnancy and childbirth, changes in the quality of pelvic tissues, and the structure of the female urinary tract. Both men and women also can become incontinent due to neurological injury, birth defects, strokes, multiple sclerosis, or previous pelvic surgeries.
There are many treatment options for urinary incontinence, including exercise, physical therapy, and surgery. If surgery is required, there are minimally invasive procedures that allow a woman to get back to her active life sooner. One of the latest developments is the tension-free suburethral sling, a thin piece of mesh inserted to support the urethra.
For some patients, the problem can be resolved with a simple office procedure in which the urethral sphincter is strengthened with injections of special bulking agents that increase the resistance in the urethra.
There are many options available for all types of urinary incontinence.
The faculty is available for services at RWJUH as well as to assist physicians in area hospitals.
Juana Hutchinson-Colas, MD, MBA
Associate Professor, Department of Obstetrics, Gynecology and Reproductive Sciences
Chief, Division of Urogynecology and Reconstructive Pelvic Surgery
Faculty
Juana Hutchinson-Colas, MD, MBA
Professor
Chief, Urogynecology and Reconstructive Pelvic Surgery
Co-Director, Pelvic Floor and Incontinence Program
Welcome to the Division of Maternal-Fetal Medicine. Our mission is to achieve the best perinatal outcomes for mothers and babies by providing the best in pregnancy-related healthcare for high-risk obstetric patients. The medical faculty offers consultation services throughout central and southern New Jersey.
Todd Rosen, MD
Professor of Obstetrics, Gynecology, and Reproductive Sciences
Chief, Division of Maternal-Fetal Medicine
Director of the Maternal-Fetal Medicine Fellowship
Fellowship
Maternal-Fetal Medicine Fellowship
The fellowship in Maternal-Fetal Medicine is a three-year fellowship designed to provide comprehensive exposure to all areas of our discipline.
Elena Ashkinadze, CGC
Associate Professor, Clinical Genetics
Supervisor, Genetic Counseling and Reproductive Genetics
Co-Director, Pregnancy Loss Evaluation Service
Julia Knypinski, MD
Assistant Professor
William MacMillan, MD
Assistant Professor
Haylea Sweat Patrick, MD
Assistant Professor
Todd Rosen, MD
Professor
Chief, Division of Maternal-Fetal Medicine
Director, Maternal-Fetal Medicine Fellowship
Emily Rosenfeld, DO
Instructor
Deepika Sagaram, MD
Assistant Professor
Ruchira Sharma, MD
Assistant Professor
Clinical Care Services
Accordion Content
High-risk Pregnancy Evaluation and Consultation Service
24-hour High Risk Pregnancy Coverage
Critical Care Obstetrics
Center for Fetal Diagnosis and Therapy with high-level fetal ultrasound including 3D/4D technology
First trimester genetic/aneuploidy screening (ultrasound and blood test)
Center for Clinical Outcomes and Continuous Quality Improvement
Genetic Counseling Service
Section of Perinatal Genetics
The Section of Perinatal Genetics is a comprehensive clinical service that evaluates, diagnoses, manages, and treats defects before birth. These may involve chromosomal abnormalities, hereditary disorders, and metabolic conditions before and during pregnancy, as well as structural anatomical defects during pregnancy. The Section of Perinatal Genetics is part of the Division of Maternal-Fetal Medicine in the Department of Obstetrics, Gynecology, and Reproductive Sciences.
The Section is professionally staffed with Master-level trained and board-certified (or board-eligible) genetic counselors. As a part of the Division of Maternal-Fetal Medicine, close collaboration exists with high-risk obstetricians and antepartum testing to ensure coordinated care. Collaborative efforts among geneticists, maternal-fetal medicine, neonatology, and pediatric specialists as well as primary care providers improve pregnancy management and neonatal outcomes by permitting earlier diagnosis and therapeutic intervention for many fetal defects and genetic disorders.
Genetic counseling is a process of educating patients about risks to their pregnancy due to age, screening results, ultrasound findings, family history, and other concerns. In addition to defining risks, genetic counselors will explain the diagnostic testing and screening options available to ensure the best pregnancy outcome.
A typical genetic counseling appointment lasts 30-60 minutes. Many patients will bring their partner or another support person to the session. The genetic counselor will draw and analyze the family tree and ask questions regarding the patient’s and partner’s family history.
The medical and pregnancy history of each member of the couple will be reviewed, including the outcomes of all previous pregnancies and exposures or medications during the current pregnancy. The genetic counselor will review prenatal test results, including blood work, ultrasound examinations, and diagnostic test results, and explain in detail if any concerns were identified. They will analyze this information to help assess the risk of having a child with a birth defect, intellectual disability, genetic disease, or a chromosome abnormality.
All the available prenatal screening and diagnostic testing options will be reviewed in detail using diagrams and other visual aids, and questions are encouraged. They will help coordinate additional recommended testing with the appropriate laboratories and physicians. A letter will be sent to the referring physician summarizing the genetic counseling session and any care recommendations.
Most patients who undergo genetic counseling are reassured about their baby’s health.
Communication regarding genetic counseling services is available in English, Russian, Mandarin, Gujarati, and Hindi. For all other languages, interpreter services are available.
Indications for Referral
Common reasons for referral during pregnancy include:
As women get older, they have an increased risk for a pregnancy with a chromosome problem. Typically, women 35 and older seek genetic counseling to learn about the different blood tests, ultrasounds, and diagnostic testing such as chorionic villus sampling and amniocentesis. Genetic counselors can help women, of any age, determine a plan for testing that is right for them.
The father’s age is important as well. As men age, they have an increased risk for a child with certain birth defects, chromosome problems, genetic conditions, and autism. Genetic counselors can educate individuals about these risks and determine a plan for testing during the pregnancy.
Regardless of the age of the parents, all women have a range of testing options available during their pregnancy to check for fetal chromosome problems. These include first-trimester screening, cell-free DNA (NIPS), level II anatomy ultrasound, chorionic villus sampling, and amniocentesis.
Genetic counseling can help clarify a testing strategy for patients that aligns with their desired outcomes, whether considered high risk because of maternal age, or just interested in prenatal testing.
Patients who have an abnormal first-trimester screen, increased nuchal translucency, abnormal NIPS result, or abnormal ultrasound finding can be referred for an explanation of the finding(s) and discussion regarding further fetal evaluation.
Patients who have an abnormal CVS or amniocentesis result may also be referred for a detailed discussion regarding the clinical features of the condition and to review their options for pregnancy management.
Couples who have had a child affected by a genetic condition, intellectual disability, autism, or birth defect and are concerned regarding the risk of recurrence for future children would benefit from genetic counseling.
Couples related by blood, such as first or second cousins, can be referred for family history evaluation and discussion regarding the risks to their unborn child.
Blood tests for the couple can be arranged to determine their risk and additional testing during pregnancy and after birth may be arranged.
Patients who are concerned regarding medication, x-ray exposure, alcohol, illicit drug exposure, or occupational exposure can be referred to assess the potential risk to the developing fetus.
Individuals who have a personal history or family history of birth defects or genetic conditions seek genetic counseling to understand if the condition can affect their unborn child.
Often blood tests can be arranged to determine if a future child is at risk and a plan can be made for reducing the risk of having an affected child.
Specialized Services
We offer several specialized services in addition to our common indications for referral, including:
Patients who have a history of recurrent miscarriage, infertility, or stillbirth can be referred for assessment to determine if a genetic or chromosomal cause is contributing to their adverse reproductive history.
For couples who are planning a pregnancy, genetic counseling is important to review their family history and arrange blood work to determine if they may be at risk for a child with a genetic disorder. Identifying at-risk couples before pregnancy is crucial because they would have the option of in vitro fertilization and transferring embryos that are free of that disease.
In the age of direct-to-consumer testing such as 23andMe, we can work with patients to help them understand their results and arrange confirmatory testing through a medical lab, when confirmation is necessary for medical management.
When a patient has a family history of cancer, genetic counseling is available to help understand their risk and the option of genetic testing for genes associated with familial cancers.
If you are concerned or need confirmation during pregnancy about the paternity of your fetus, we are available to arrange testing (blood test or diagnostic testing such as CVS or amniocentesis) to confirm the paternity of your fetus. An appointment with our genetic counselors can help you understand your options, cost, and timing of the testing.
Perinatal Translational Research Laboratory
Message from the Director
Preterm birth is the leading cause of morbidity and mortality of newborn infants in the United States. It occurs in one in every 12 pregnancies with an annual economic burden of 26 billion dollars. According to the CDC, preterm-related causes of death together accounted for 35% of all infant deaths in 2010, more than any other single cause. Preterm birth is also a leading cause of long-term neurological disabilities in children.
Spontaneous preterm birth is a physiologically heterogeneous syndrome and the mechanisms could be influenced by environmental stimuli, genetic predisposition, and epigenetic conditions. Our lab is focused on a better understanding of the mechanisms that lead to the onset of labor at term, thereby facilitating discoveries of new targets for pharmacologic therapy to arrest labor when it occurs too early.
While the complex mechanisms of timing human birth remain elusive, a major role has been proposed for the placenta. Several studies support the existence of a placental clock that determines the length of human pregnancy. Recently we have determined that an epigenetic switch is ultimately responsible for the positive regulation of corticotropin-releasing hormone (CRH), part of the placental clock, by glucocorticoids as gestation advances.
Bingbing Wang, PhD
Laboratory Director
Assistant Professor of Obstetrics and Gynecology
PhD, University of Washington
Post-doctorate, Dana-Farber Cancer Institute
Email: wangbi@rwjms.rutgers.edu
Research
At present, we are employing epigenetic, genomic, proteomic, and biochemical approaches in both in vitro (primary trophoblast and human embryonic stem cells) and in vivo (non-human primate) models, to understand the molecular regulation and functions of “pro-labor” genes as well as the pathway(s) leading to functional withdrawal of progesterone in the context of initiation of human labor at term.
(* indicates corresponding authors)
DiStefano V, Wang B*. Parobchak N, Roche N, Rosen T* (2015). RelB/p52-associated CBP/HDAC1 mediate acetylation/de-acetylation of H3K9 to upregulate CRH in term human placenta. Sci Signal (In press) (Selected for Podcast).
Rosen T*, Schulkin J, Power M, Tadesse S, Norwitz ER, and Wang B* (2015). Comparative immunohistochemistry of placental CRH and RelB/NF-κB2 between human and non-human primates. Comparative Med. 65:140-143.
Yu LJ, Wang B*, Parobchak N, Roche N, Rosen T* (2015). STAT3 cooperates with the non-canonical NF-κB signaling to regulate pro-labor genes in the human placenta. Placenta. 36:581-586.
Wang B*, Parobchak N, Rosen M, Roche, N, and Rosen T* (2014). Negative effects of progesterone receptor isoform-A on human placental activity of the non-canonical NF-κB signaling. J Clin Endocrinol Metab. 99:E320-328.
Wang B*, Palomares K, Parobchak N, Cece J, Rosen M, Nguyen A, Rosen T* (2013). Glucocorticoid receptor signaling contributes to constitutive activation of the noncanonica NF-κB pathway in term human placenta. Mol Endocrinol 27:203-211 (Featured in Endocrine News, April, 2013).
Wang B*, Parobchak N, and Rosen T* (2012). RelB/NF-κB2 regulates corticotropin-releasing hormone in the human placenta (2012). Mol Endocrinol 26:1356-1369 (Featured in Endocrine News, August, 2012).
Wang XK, Agarwal M, Parobchak N, Rosen A, Vetrano AM, Srinivasan A, Wang B*, Rosen T* (2016). Mono-(2-Ethylhexyl) Phthalate Promotes Pro-Labor Gene Expression in the Human Placenta. PLoS One. 11(1):e0147013. doi: 10.1371/journal.pone.0147013. eCollection 2016.
Di Stefano V, Wang B*, Parobchak N, Roche N, Rosen T* (2015). RelB/p52-mediated NF-κB signaling alters histone acetylation to increase the abundance of corticotropin-releasing hormone in human placenta. Sci Signal. 8(391):ra85. doi: 10.1126/scisignal.aaa9806.
Rosen T*, Schulkin J, Power M, Tadesse S, Norwitz ER, and Wang B* (2015). Comparative immunohistochemistry of placental CRH and RelB/NF-κB2 between human and non-human primates. Comparative Med. 65:140-143.
Yu LJ, Wang B*, Parobchak N, Roche N, Rosen T* (2015). STAT3 cooperates with the non-canonical NF-κB signaling to regulate pro-labor genes in the human placenta. Placenta. 36:581-586.
Wang B*, Parobchak N, Rosen M, Roche, N, and Rosen T* (2014). Negative effects of progesterone receptor isoform-A on human placental activity of the non-canonical NF-κB signaling. J Clin Endocrinol Metab. 99:E320-328.
Wang B*, Palomares K, Parobchak N, Cece J, Rosen M, Nguyen A, Rosen T* (2013). Glucocorticoid receptor signaling contributes to constitutive activation of the noncanonica NF-κB pathway in term human placenta. Mol Endocrinol 27:203-211 (Featured in Endocrine News, April, 2013).
Horman SR, Janas MM, Litterst C, Wang B, MacRac IJ, Sever MJ, Morrissey DV, Luo B, Novina CD, and Orth AP (2013). Akt-mediated phosphorylation of Argonaute 2 down-regulates cleavage and upregulates translational repression of microRNA targets. Mol Cell 50:356-367.
Wang B*, Parobchak N, and Rosen T* (2012). RelB/NF-κB2 regulates corticotropin-releasing hormone in the human placenta (2012). Mol Endocrinol 26:1356-1369 (Featured in Endocrine News, August, 2012).
Janas MM, Wang B, Harris AS, Shaffer JM, Subrahmanyam Y, Behlke M, Wucherpfennig K, Gagnon E, Novina CD (2012). Alternate RISC assembly: binding and repression of microRNA-mRNA duplexes by human Ago proteins. RNA 18:2041-2055.
Li S, Zhu J, Zhang W, Chen Y, Zhang K, Popescu LM, Ma X, Lau WB, Rong R, Yu X, Wang B, Li Y, Xiao C, Zhang M, Wang S, Yu L, Chen AF, Yang X, and Cai J (2011). Signature microRNA expression profile of essential hypertension and its link to human cytomegalovirus infection. Circulation 124:175-184.
Wang B, Li S, Qi HH, Chowdhury D, Shi Y, and Novina CD (2009). Distinct passenger strand and mRNA cleavage activities of human Argonaute proteins. Nat Struct Mol Biol. 16:1259-1266 (Selected for Faculty of 1000).
Wang B, Yanez A, and Novina CD. miRNA repressed mRNAs contain 40S, but no 60S components (2008). Proc Natl Acad Sci USA 105:5343-5348 (Featured in Cell’s Leading Edge series).
Wang B, Love TM, Call ME, Doench JG, and Novina CD (2006). Recapitulation of short RNA-directed translational gene silencing, in vitro. Mol Cell 22:553-560.
Domingo GJ, Palazzo SS, Wang B, Pannicucci B, Salavati R, and Stuart KD (2003). Dyskinetoplastic Trypanosoma brucei contain functional editing complexes. Eukaryot Cell 2:569-577.
Panigrahi AK, Schnaufer A, Ernst NL, Wang B, Salavati R, and Stuart KD (2003). Identification of novel components of Trypanosoma brucei editosomes. RNA 9:484-492.
Wang B, Palazzo S, Ernst N, Panigrahi A, Salavati R, and Stuart KD (2003). TbMP44 is essential for RNA editing and structural integrity of the editosome in Trypanosoma brucei. Eukaryot Cell 2:578-587.
Wang B, Salavati R, Heidmann S, and Stuart K (2002). A hammerhead ribozyme substrate and reporter for in vitro kinetoplastid RNA editing. RNA 8:548-554.
Rosen T, Schatz F, Kuczynski E, Lam H, Koo AB, Lockwood CJ (2002). Thrombin-enhanced matrix metalloproteinase-1 expression: a mechanism linking placental abruption with premature rupture of the membranes. J Matern Fetal Neonatal Med 11:11-17
Rosen T, Kuczynski E, O'Neill LM, Funai EF, Lockwood CJ (2001). Plasma levels of thrombin-anthithrombin complexes predict preterm premature rupture of the fetal membranes. J Matern Fetal Neonatal Med 10:297-300.
Radunovic N, Kuczynski E, Rosen T, Dukanac J, Petkovic S, Lockwood CJ (2000). Plasma apolipoprotein A-I and B concentrations in normal and growth retarded fetuses: A potential mechanism for the association of low birth weight with adult atherosclerosis. J Clin Endocrinol Metab. 85:85-88.
Rosen T, Krikun G, Ma YH, Wang E-Y, Lockwood CJ Guller S (1998). Chronic antagonism of nuclear factor-kappaB activity in cytotrophoblasts by dexamethasone: A potential mechanism for antiinflammatory action of glucocortiocoids in human placenta. J Clin Endocrinol Metab. 83:3647-52.
Di Stefano, V. Santolaya-Forgas, J. Faro, R. Duzyj, C. Oyelese, Y. Mode of Delivery in Stillbirth, 1995-2004. Reprod Sci, 2015 Epub ahead of print.
Duzyj, CM. Buhimschi, IA. Motawea, H. Laky, CA. Cozzini, G. Zhao, G. Funai, EF. Buhimschi, CS. The Invasive Phenotype of Placenta Accreta Extravillous Trophoblasts Associates with Loss of E-Cadherin. Placenta, 2015 36(6):645-51.
Duzyj, CM. Paidas, MJ. Jebailey L, Huang SJ, Barnea ER. PreImplantation Factor (PIF*) promotes embryotrophic and neuroprotective decidual genes: effect negated by epidermal growth factor. J Neurodev Disord, 2014 6:36.
Nayeri, UA. Buhimschi, IA. Laky, CA. Cross, SN. Duzyj, CM. Ramma, W. Sibai, BM. Funai, EF. Ahmed, A. Buhimschi, CS. Antenatal corticosteroids impact the inflammatory rather than the antiangiogenic profile of women with preeclampsia. Hypertension, 2013 63(6):1285-92.
Rosenberg, V. Buhimschi, I. Dulay, A. Abdel-Razeq, S. Oliver, E. Duzyj, C. Lipkind, H. Pettker, C. Buhimschi, C. Modulation of amniotic Fluid activin-a and inhibin-a in women with preterm premature rupture of the membranes and infection-induced preterm birth. American Journal of Reproductive Immunology, 2012 67(2):122-31.
Buhimschi, I. Oliver, E. Ali, U. Laky, C. Cakmak, H. Duzyj, C. Zhao, G. Buhimschi, C. Novel insights into the mechanisms responsible for the up-regulation of the soluble receptor for advanced glycation end-products (sRAGE) in severe preeclampsia (sPE). American Journal of Obstetrics and Gynecology, 2011 204(1):s13.
Duzyj, C. Barnea, E.R. Li, M. Huang, S.J. Krikun, G. Paidas, M.J. Preimplantation Factor Promotes First Trimester Trophoblast Invasion. American Journal of Obstetrics and Gynecology. 2010 203(4):402.e1-402.e4. Lipkind, H.S.
Duzyj, C. Rosenberg, T.J. Funai, E.F. Chavkin, W. Chaisson, M.A. Disparities in Cesarean Rates and Associated Adverse Neonatal Outcomes in New York City Hospitals. Obstetrics and Gynecology. 2009 113(6):1239-1247.
Diaz, L.A. Pai, R. Endres, J. Anthony, P. Duzyj, C. Bishu, S. Morita, Y. Fox, D.A. Xenogeneic cells and superantigen induce human T-cell activation in the absence of T-cell recognition of xenoantigen, The Journal of Laboratory and Clinical Medicine, 2003 142(3):149-157.
Wang B, Doench J, and Novina CD (2007). Analysis of miRNA effector functions in vitro. Methods 43:91-104.
Stuart KD, Salavati R, Igo R. Jr., Ernst NL, Palazzo SS, and Wang B (2004). Kinetoplastid RNA editing: uridylate insertion and deletion. Methods Mol Biol 265:251-272.
Faculty and Staff
Todd Rosen, MD
Chief, Division of Maternal-Fetal Medicine
MD, New Jersey Medical School
MFM Fellowship, New York University
Board Certified: OB/GYN and Maternal-Fetal Medicine
Special Interests: Prenatal diagnosis, multiple pregnancies, preterm labor, recurrent pregnancy loss
Contact Us
Contact the Division of Maternal-Fetal Medicine
Robert Wood Johnson University Hospital
One Robert Wood Johnson Place
New Brunswick, NJ 08901
Telephone: (732) 235-8006
Fax: (732) 235-6650
Appointments: (732) 235-8006
Our Office Location:
125 Paterson Street
New Brunswick, NJ
Message from the Chief
The Department of Obstetrics, Gynecology, and Reproductive Sciences provides high-quality comprehensive reproductive health care, teaching, and research through its affiliation with the world's largest provider of fertility services, IVI-RMA. Subspecialty providers in reproductive endocrinology and infertility are academically and clinically focused, and they are trained to diagnose and manage the most complicated disorders that affect women’s reproductive health. Physicians at Reproductive Medicine Associates of New Jersey (RMA of NJ) are members of the RWJMS volunteer faculty and hold clinical academic titles. Our medical students and Ob/Gyn residents rotate through various clinical sites throughout the state. RMA of NJ has served as the Reproductive Endocrinology & Infertility Division for Robert Wood Johnson Medical School since 2006.
IVI-RMA is a recognized global leader in reproductive medicine and the largest among the most experienced, and successful centers for infertility treatment. Treatment centers are located throughout the world. You can learn more about RMA of NJ on their website (https://rmanetwork.com).
You may also speak directly with an RMA of NJ patient coordinator by calling 866-762-3140. They can provide information about the physicians and clinical programs at RMA of NJ, answer any questions about insurance, and, if appropriate, will be able to schedule an appointment for your patients.
Mark V. Sauer, MD, MS Professor
Senior Associate Dean for Women’s Health, Rutgers Robert Wood Johnson Medical School
